Loading provider…
Loading provider…
Rheumatology Physician in Mesquite, TX
NPI: 1346256773Primary Practice Location
Southwest Arthritis Research Group PA
1600 Republic Pkwy, Mesquite, TX
Primary Employer
Southwest Arthritis Research Group PA
myarthritisdoc.com
HQ Phone
Get M.D. FACR Atul's Phone Numberphone_androidMobile
Get M.D. FACR Atul's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
TX State Medical License
1995 - 2026
NJ State Medical License
1994 - 1997
PA State Medical License
1992 - 1996

American Board of Internal Medicine
Rheumatology
University of Pennsylvania Health System
Fellowship • Rheumatology
1992 - 1995
Stony Brook Medicine/University Hospital
Residency • Internal Medicine
1989 - 1992
All India Institute of Medical Sciences
Medical School
Until 1987
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 49 | 83 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 37 | 54 |
| 3 | 96413Infusion of chemotherapy into a vein up to 1 hour | 34 | 184 |
| 4 | 96365Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 19 | 31 |
| 5 | 96401Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | 18 | 262 |
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Authors: Linda Belhorn, Ted Mikuls, Roy Fleischmann
Journal: N Engl J Med
Authors: Hileti, Dona, Demetriou, Christiana A, Iasonides, Michalis C, Pipis, Spyros, Mahmood, Amna, Lanigan, Julie, Singhal, Atul
Journal: J Nutr
Publication Date: 2023-06-17
Lead Sponsor: Jeffrey Curtis
Collaborators: AbbVie, Bristol-Myers Squibb, University of Pennsylvania, Pfizer, Eli Lilly and Company, University of Alabama at Birmingham, Novartis, University of Nebraska, Illumination Health
Intervention / Treatment: DRUG: Upadacitinib, DRUG: TNF Inhibitor, DRUG: Baricitinib, DRUG: Ixekizumab, DRUG: Secukinumab, DRUG: Abatacept, DRUG: Tofacitinib, DRUG: Canakinumab Injection
Lead Sponsor: Galvani Bioelectronics
Collaborators: Q2 Solutions, NAMSA
Intervention / Treatment: DRUG: Baricitinib, DEVICE: Sham Stimulation, DRUG: Background Treatment, DEVICE: Active Stimulation
Lead Sponsor: Swedish Orphan Biovitrum
Intervention / Treatment: OTHER: Normal Saline, DRUG: SEL-212 high-dose, DRUG: SEL-212 low-dose